-
GLT-1, CB1-CREB Signaling, and TBI Cognition
2026-09-30
This 2025 Biomolecules study identifies an astrocyte-centered mechanism linking elevated 2-AG, CB1 activation, reduced CREB phosphorylation, and loss of GLT-1 after traumatic brain injury. In mice, pharmacological CB1 blockade with AM 281 restored GLT-1-associated glutamate control, reduced neuronal apoptosis, and improved behavioral measures of cognitive function.
-
BIRB 796: Rethinking p38α Translation
2026-09-30
BIRB 796, or Doramapimod, illustrates how selective allosteric kinase inhibition can connect target engagement, inflammatory signaling, apoptosis, and translational decision-making. This article interprets recent p38α conformational biology and provides practical guidance for designing mechanistically informative inflammation and cancer studies without overstating clinical relevance.
-
(R)-MG132 for Proteasome Validation
2026-09-29
(R)-MG132 is a functionally inactive MG-132 enantiomer designed to separate proteasome-dependent biology from solvent, peptide-aldehyde, and cellular stress effects. Its matched-control role is especially valuable when testing ubiquitin-proteasome mechanisms alongside HNRNPU lactylation, PHGDH expression, and cancer-metabolism phenotypes.
-
L-Leucine for Nucleic Acid LNP Drying
2026-09-29
L-Leucine can be screened as a formulation aid when converting nucleic acid–lipid nanoparticles from liquid dispersions into dry powders. This workflow connects excipient selection with freeze-drying, spray-based processing, reconstitution testing, and potency preservation without treating one composition as universally optimal.
-
AM 281: A Causal Lens on CB1-CREB-GLT-1
2026-09-28
AM 281 offers translational researchers a selective pharmacological route to test how CB1 activity shapes astrocytic GLT-1 regulation, glutamate excitotoxicity, and cognitive outcomes. This thought-leadership analysis connects recent traumatic brain injury findings with experimental strategy for neuropharmacology and addiction-related cognition research.
-
Phosphatase Inhibitor Cocktail: K1015 Workflow
2026-09-28
Phosphatase Inhibitor Cocktail (2 Tubes, 100X) helps limit loss of protein phosphorylation during sample preparation for immunoblotting, immunoprecipitation, kinase assays, and phosphoproteomics. Use it during research sample processing, not as a treatment reagent or without validation in a downstream enzyme reaction; it is not for diagnostic or medical use.
-
Hematoxylin B3671: Nuclear Staining Workflow
2026-09-27
Hematoxylin B3671 is a solid nuclear stain for researchers preparing histological or cytological samples, including established hematoxylin and eosin workflows. It is a research reagent, not a complete staining kit, and is not intended for diagnostic, clinical, or medical use.
-
Irinotecan Workflows for Colorectal Cancer Research
2026-09-26
Build reproducible colorectal cancer experiments around Irinotecan’s conversion to SN-38, with practical guidance for dose selection, viability assays, and DNA-damage readouts. The workflow pairs cell-line-specific benchmarks with solvent, activation, and toxicity controls so results are easier to interpret—not just easier to generate.
-
BCA Protein Quantification Kit K4102 Guide
2026-09-25
The Bicinchoninic Acid Assay (BCA) Protein Quantification Kit K4102 measures total protein in low-concentration samples, including many detergent-containing preparations and cell lysates. It is intended for research workflows such as sample normalization, not diagnostic, clinical, or medical testing.
-
Cav2.1 Blockade Suppresses Rat Kindling Seizures
2026-09-25
In a rat chemical-kindling model, the Cav2.1 blocker ω-agatoxin IVA delayed seizure onset and reduced the development of kindling and epileptic discharges without detectable motor-coordination impairment. The study also found higher BDNF and lower cleaved caspase-3 immunoreactivity, offering neuroprotective clues while leaving open whether these molecular changes cause the seizure effects.
-
Cy3-UTP for Mapping RNA Architecture
2026-09-24
Cy3-UTP can make in vitro-transcribed RNA visible, but fluorescent signal is only useful when labeling is designed around the biology being measured. This article connects Cy3-modified uridine triphosphate to recent findings on 28S rRNA expansion segments, highlighting controls that help distinguish RNA localization from RNA-driven architecture.
-
Resazurin Sodium Salt for Metabolic Assay Design
2026-09-24
Resazurin sodium salt converts cellular reducing activity into a fluorescent signal, but that signal can shift when metabolism changes independently of cell number. This article connects assay interpretation to research on glutamine metabolism in hepatic stellate cells and offers practical guidance for using the readout responsibly.
-
BCA Protein Quantification Kit: K4102 Workflow
2026-09-23
The K4102 Bicinchoninic Acid Assay (BCA) Protein Quantification Kit measures total protein in dilute samples, including many preparations containing ionic or non-ionic detergents. Use it for research workflows such as cell-lysate normalization, not for diagnostic, clinical, or medical testing.
-
BCA Protein Quantification Kit K4102 Guide
2026-09-23
The BCA Protein Quantification Kit (SKU K4102) provides a practical method for measuring low-concentration total protein in biochemical samples, including many detergent-containing preparations and cell lysates. It is intended for scientific research workflows such as sample normalization and is not for diagnostic, clinical, or medical use.
-
SIRT1, Resveratrol, and Mitochondrial Biogenesis
2026-09-22
The 2024 reference study identifies a SIRT1–PGC-1α–TFAM pathway that links prion peptide stress to impaired mitochondrial biogenesis, mitochondrial dysfunction, and apoptosis in N2a cells. Its use of resveratrol as a pharmacological SIRT1 activator supports a pathway-resolved neuroprotection workflow, while remaining limited to an in vitro prion-peptide model.